Proteomics offers considerable opportunities for either enhancing our biological understanding or discovering
biomarkers, blood and biopsied specimen-based proteomic approaches, provide reproducible and quantitative tools that can
complement clinical assessments and aid clinicians in the diagnosis and treatment of
inflammatory bowel disease (IBD). Sometimes a differential diagnosis of
Crohn's disease (CD) and
ulcerative colitis (UC) and the prediction of treatment response can be deduced by finding meaningful
biomarkers, for which the central platform for proteomics is tandem mass spectrometry (MS/MS). A range of workflows are available for
protein (or
peptide) separation prior to MS/MS as well as bioinformatics analysis to achieve
protein identification, for which two-dimensional electrophoresis (2-DE) and subsequent mass spectrometry (MS), liquid chromatography-MS, difference gel electrophoresis following 2-DE, isobaric tags for relative and absolute quantification (iTRAQ), stable
isotope labeling by
amino acids and label-free quantification are under development. In this article, the current status and perspective of these advanced proteomic technologies are introduced, with examples of recent
biomarkers focused on the diagnosis, treatment response, prognosis of IBD, and even
colitis-associated
carcinogenesis in both animal models and human patients.